通过增强GLUT4转位的小分子增强胰岛素敏感性
Terry C Yin1, Jonathan G Van Vranken2, Dhiraj Srivastava3
1Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA 52242, USA; Fraternal Order of Eagle Diabetes Research Center, University of Iowa, Iowa City, IA 52242, USA; Pappajohn Biomedical Institute, University of Iowa, Iowa City, IA 52242, USA.
Cell chemical biology
|July 15, 2023
概括
研究人员发现了新的小分子,通过向Unc119蛋白质来增强胰岛素作用. 这些化合物通过改善胰岛素敏感性和葡萄糖吸收,显示出治疗II型糖尿病的潜力.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰岛素抵抗 (IR) 是第二类糖尿病的主要驱动因素,安全的治疗选择有限.
- 目前针对IR的治疗方法往往具有副作用或有效性有限.
研究的目的:
- 识别能够增强胰岛素作用并改善胰岛素敏感性的新型小分子.
- 阐明这些已识别的胰岛素敏感剂的分子标和机制.
主要方法:
- 高通量选试验测量实时葡萄糖载体4 (GLUT4) 转位.
- 在胰岛素抵抗模型中的体内研究.
- 基于蛋白质和CRISPR的方法用于目标识别.
- 结构生物学来确定Unc119化合物的复杂结构.
主要成果:
- 识别增强胰岛素刺激GLUT4转位的小分子.
- 在体内表现出改善的葡萄糖耐受性和吸收.
- Unc119蛋白质被确定为这些胰岛素敏感剂的分子标.
- 与已识别的化合物结合的Unc119的结构阐明.
结论:
- 发现了针对Unc119蛋白质的新型胰岛素敏感剂.
- 这些化合物有可能发展成为安全有效的糖尿病治疗方法.
- Unc119蛋白质代表了治疗胰岛素耐药性治疗干预的有希望的新目标.
相关概念视频
Glucagon-like Receptor Agonists
364
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
364
Oral Hypoglycemic Agents: Biguanides and Glitazones
236
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
236
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Glucose Absorption Into the Small Intestine
31.8K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.8K


